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Letter to the editor
Treating sinonasal crusting and infection after palatal and sinonasal cancer resection with topical
antibiotic irrigations
After palatal or sinonasal cancer resections with or without midface
and nasal reconstruction, there can be a significant amount of exposed
bone in the sinonasal cavities. Until the exposed bone is remucosalized
through wound healing, sinonasal crusting ensues and can inhibit
wound healing [1,2]. Concurrently, the intact or regenerated sinonasal
mucosa will secrete mucus, and the obstructive crusting will promote
mucostasis and infection. Additionally, free tissue transferred to this
region to reconstruct the maxillary defect lacks respiratory epithelium,
which could further promote sinonasal crusting, mucostasis, and infec
tion. This local infectious rhinosinusitis can significantly decrease
quality of life, in patients who have already been through significant
physical and emotional stress from their head and neck cancer man
agement [2–4].
Sinonasal crusting, with or without infection, is a very common
postoperative complication after sinonasal and skull base surgery,
occurring in up to 98% of patients [2]. Despite how common crusting
and infection can be after these surgeries, very little has been published
with regard to treating this frustrating postoperative condition. How
ever, there have been some encouraging outcomes in the rhinologic
literature on managing local sinonasal infection and crusting with
topical intranasal antibiotics in the setting of refractory chronic rhino
sinusitis (CRS) [5,6]. These practices could be applied to head and neck
cancer patients after palatal and sinonasal cancer resection and recon
struction for sinonasal crusting and infections.
Topical intranasal antibiotics have received less attention in the
literature for CRS management compared to topical saline and steroids
[5,6]. While publications have shown mixed results with different
classes and formulations of topical antibiotics for sinusitis management,
reviews have suggested them as an option for refractory CRS cases,
especially after sinus surgery and with culture-directed therapy [5,6].
Amongst reported topical intranasal antibiotics for rhinosinusitis,
mupirocin has shown most promise in managing CRS with associated
Staphylococcus aureus (S. aureus) infection [7].
S. aureus is one of the most common organisms associated with
postoperative sinonasal infection, and can produce biofilms that are
100–1000 times more resistant to antibiotics than their planktonic forms
[7]. Given the potential for biofilm production in refractory sinusitis, it
has been suggested that topical antibiotics be formulated with antibiofilm intent [8]. Notably, Ha et al. performed in vitro testing of
mupirocin on S. aureus and showed that a concentration of 125 μg/mL
was able to reduce biofilm mass by over 90% [7].
As important as the antibiotic itself, is the mechanism of drug de
livery. Low-volume sprays and nebulizers are inadequate for delivering
antibiotics topically into all sinus cavities, and they also do not provide
the force necessary to mechanically debride dense sinonasal crusting
[5]. Multiple studies have shown no clinical improvements in CRS when

applying topical antibiotics with low volume delivery devices. Instead,
topical antibiotics should be dissolved in saline and delivered through a
high-volume irrigation device that can deliver at least 100 mL per side
[5,9].
Regarding clinical studies demonstrating benefit from topical
mupirocin irrigations, Jarvis-Brady et al. showed in a small randomized
trial that 1 month of culture-directed mupirocin irrigations out
performed saline irrigations in short-term treatment of 25 patients with
surgically recalcitrant S. aureus positive CRS [8]. Uren et al. also showed
in a small prospective cohort study that mupirocin irrigations improved
endoscopic and symptom scores in 16 S. aureus positive CRS patients. In
this study, 15 of 16 patients’ cultures were negative after treatment,
though no long-term follow-up was reported [10].
Reported risks with topical antibiotic irrigations have been minimal.
Topical antibiotics such as mupirocin undergo rapid degradation with
minimal penetration into serum, so should pose minimal risk to patients.
Most commonly reported side effects include local irritation with
headaches or burning sensation, though these issues are rare [9]. Anti
microbial resistance is a potential concern as well. Resistance rates of
11–65% have been reported in areas of widespread topical mupirocin
use. Therefore, short-term use is typically recommended [9].
Based on the aforementioned features, in the setting of sinonasal
crusting and local infection after palatal or sinonasal cancer resection
and reconstruction, the authors empirically initiate topical antibiotic
high volume irrigations with mupirocin 30 mg dissolved in 240 mL sa
line (125 μg/mL). This antibiotic solution is delivered through a 240 mL
delivery device, with half of the solution being delivered through each
nasal cavity, twice daily. Antibiotic solution formulation can be ach
ieved through local or mail order pharmacies, as formulation capabil
ities differ between pharmacies. If there is purulence associated with the
crusting, then the purulence is cultured, and culture-directed topical
antibiotic irrigations are implemented. To reduce the risk of developing
resistance, the authors prescribe the antibiotic irrigations for 1–2
months at a time, then reassess with nasal endoscopy to follow progress.
In-office sinonasal debridement to remove excess crusting may also be
necessary to optimize topical drug delivery to the underlying mucosa.
In summary, patients frequently develop sinonasal crusting with or
without infection after palatal or sinonasal cancer resection and recon
struction. While more research is necessary to demonstrate the efficacy
of high volume topical antibiotic irrigations, they are a viable option for
managing local sinonasal crusting and infection after these complex
cancer resections.
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